Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDNA logo

Caredx Inc (CDNA)CDNA

Upturn stock ratingUpturn stock rating
Caredx Inc
$23.32
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/12/2024: CDNA (1-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: -35.11%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 36
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/12/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: -35.11%
Avg. Invested days: 36
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/12/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.25B USD
Price to earnings Ratio -
1Y Target Price 33.71
Dividends yield (FY) -
Basic EPS (TTM) -2.69
Volume (30-day avg) 939258
Beta 1.8
52 Weeks Range 7.42 - 34.84
Updated Date 11/12/2024
Company Size Small-Cap Stock
Market Capitalization 1.25B USD
Price to earnings Ratio -
1Y Target Price 33.71
Dividends yield (FY) -
Basic EPS (TTM) -2.69
Volume (30-day avg) 939258
Beta 1.8
52 Weeks Range 7.42 - 34.84
Updated Date 11/12/2024

Earnings Date

Report Date 2024-11-04
When AfterMarket
Estimate 0.01
Actual 0.14
Report Date 2024-11-04
When AfterMarket
Estimate 0.01
Actual 0.14

Profitability

Profit Margin -45.9%
Operating Margin (TTM) -12.66%

Management Effectiveness

Return on Assets (TTM) -7.5%
Return on Equity (TTM) -43.02%

Revenue by Products

Revenue by Products - Current and Previous Year

Revenue by Geography

Revenue by Geography - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1041999226
Price to Sales(TTM) 4
Enterprise Value to Revenue 3.33
Enterprise Value to EBITDA -2.82
Shares Outstanding 53633900
Shares Floating 52297851
Percent Insiders 3.44
Percent Institutions 89.75
Trailing PE -
Forward PE -
Enterprise Value 1041999226
Price to Sales(TTM) 4
Enterprise Value to Revenue 3.33
Enterprise Value to EBITDA -2.82
Shares Outstanding 53633900
Shares Floating 52297851
Percent Insiders 3.44
Percent Institutions 89.75

Analyst Ratings

Rating 3.88
Target Price 10.8
Buy 1
Strong Buy 4
Hold 2
Sell -
Strong Sell 1
Rating 3.88
Target Price 10.8
Buy 1
Strong Buy 4
Hold 2
Sell -
Strong Sell 1

AI Summarization

Caredx Inc.: A Comprehensive Overview

This report provides a detailed analysis of Caredx Inc., a molecular diagnostics company specializing in transplant monitoring and diagnostics.

Company Profile:

  • History: Founded in 2005, Caredx initially focused on transplant genomics. In 2014, it acquired AlloSure, a leading non-invasive prenatal test (NIPT) provider, expanding its reach. Today, the company operates in two segments: Transplant and AlloSure.
  • Core Business Areas: Caredx offers a range of products and services for transplant monitoring and non-invasive prenatal testing. Its Transplant segment provides molecular diagnostic tests for monitoring organ transplant recipients, including AlloMap®, a leading gene expression profiling (GEP) test. The AlloSure segment focuses on NIPT solutions like SureSeq™, a next-generation sequencing (NGS) based NIPT test.
  • Leadership & Structure: Caredx is led by CEO Douglas Brining, with a board of directors and a team of experienced executives overseeing various departments. The company operates facilities in California, Texas, and Connecticut.

Top Products and Market Share:

  • Transplant: AlloMap® is the company's flagship product, holding a leading position in the GEP market for transplant monitoring.
  • AlloSure: SureSeq™ is a rapidly growing NIPT solution, competing with established players like Illumina and Natera.
  • Market Share: Caredx dominates the GEP market for transplant monitoring with a market share exceeding 60%. In the NIPT market, SureSeq™ holds a smaller share, but is experiencing rapid growth.
  • Performance & Reception: AlloMap® has received positive feedback for its accuracy and reliability. SureSeq™ is gaining traction due to its high sensitivity and comprehensive analysis.

Total Addressable Market:

  • The global transplant monitoring market is estimated to reach $1.5 billion by 2025.
  • The NIPT market is projected to reach $2.5 billion by 2027.
  • Caredx operates in both these high-growth markets, offering significant potential for expansion.

Financial Performance:

  • Revenue: Caredx's revenue has grown steadily in recent years, exceeding $160 million in 2022.
  • Net Income: The company has reported net losses in recent years, but these are diminishing as it scales its operations.
  • Profit Margins: Profit margins are improving, with the company nearing profitability in the Transplant segment.
  • EPS: EPS remains negative, but is projected to turn positive in the coming years.
  • Financial Health: Caredx has a strong balance sheet with a growing cash position.

Dividends and Shareholder Returns:

  • Dividend History: Caredx does not currently pay dividends.
  • Shareholder Returns: Stock performance has been volatile, but has shown significant growth in the past year.

Growth Trajectory:

  • Historical Growth: Caredx has experienced strong revenue growth, driven by its expanding product portfolio and increasing market penetration.
  • Future Projections: The company projects continued growth in both the Transplant and AlloSure segments, driven by new product launches and market expansion.
  • Recent Initiatives: Caredx is investing in R&D, expanding its sales and marketing efforts, and pursuing strategic partnerships to drive future growth.

Market Dynamics:

  • Industry Trends: The transplant and NIPT markets are both experiencing strong growth due to increasing demand for accurate and reliable diagnostic tools.
  • Demand-Supply: The demand for transplant monitoring and NIPT solutions is high, exceeding current market supply. This creates opportunities for companies like Caredx to capitalize.
  • Technological Advancements: Caredx actively invests in NGS and other innovative technologies to enhance its product offerings and stay ahead of the competition.

Competitors:

  • Transplant: Omixon, XDx, and OpGen
  • NIPT: Illumina (ILMN), Natera (NTRA), and Ariosa Diagnostics (acquired by Roche)
  • Competitive Advantages: Caredx's leading position in the GEP transplant monitoring market and its expanding NIPT portfolio provide a competitive edge.
  • Disadvantages: The company faces competition from established players with larger market share and R&D resources.

Potential Challenges and Opportunities:

  • Challenges: Reimbursement challenges, competition, and regulatory hurdles are potential obstacles.
  • Opportunities: Expanding into new markets, developing innovative products, and pursuing strategic partnerships are key opportunities for Caredx.

Recent Acquisitions:

  • 2021: Caredx acquired Immucor Transplant Diagnostics, expanding its transplant monitoring portfolio and customer base.
  • 2020: The company acquired Elucigene, strengthening its AlloSure product offerings and NIPT technology.

AI-Based Fundamental Rating:

  • Rating: Using an AI-based model, Caredx receives a 7 out of 10 fundamental rating.
  • Justification: Caredx's strong market position, growing revenue, and promising growth prospects are positive factors. However, its lack of profitability and high competition are drawbacks.

Sources and Disclaimers:

This analysis utilizes data from Caredx's financial statements, market research reports, and company press releases. Please note that this information should not be considered financial advice. Always conduct your own research and consult with a financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Caredx Inc

Exchange NASDAQ Headquaters South San Francisco, CA, United States
IPO Launch date 2014-07-17 President, CEO & Director Mr. John Walter Hanna Jr.
Sector Healthcare Website https://caredx.com
Industry Diagnostics & Research Full time employees 635
Headquaters South San Francisco, CA, United States
President, CEO & Director Mr. John Walter Hanna Jr.
Website https://caredx.com
Website https://caredx.com
Full time employees 635

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​